Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05829655 · ClinicalTrials.gov registry record · Early Phase 1
Measuring Acute Drug Demand in Humans
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 75
- Enrollment target
NCT05829655 is a Early Phase 1 study that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 75 participants.
The verdict
NCT05829655, a Early Phase 1 study, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.
Interventions
- DRUG Drug A (Blinded Drug)
- DRUG Drug B (Blinded Drug)
- DRUG Drug C (Blinded Drug)
- DRUG Drug D (Blinded Drug)
- DRUG Suvorexant (20mg/day)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2028-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05829655
The ClinicalTrials.gov registry entry for NCT05829655 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Drug A (Blinded Drug) is the first listed.
NCT05829655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05829655 about?
NCT05829655 is a clinical study titled "Measuring Acute Drug Demand in Humans". This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.
What is the current status of trial NCT05829655?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 75 participants. The study started on 2023-08-08. Estimated completion is 2028-01-01.
What interventions are being tested in trial NCT05829655?
The interventions under investigation include: Drug A (Blinded Drug) (DRUG), Drug B (Blinded Drug) (DRUG), Drug C (Blinded Drug) (DRUG), Drug D (Blinded Drug) (DRUG), Suvorexant (20mg/day) (DRUG).
Who is sponsoring clinical trial NCT05829655?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.